









Markets
/
Stocks
/
nasdaq-ardx
/

Ardelyx Inc

ARDX

6.130USD

+0.480+8.50%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.49BMarket Cap

LossP/E TTM



Ardelyx Inc

6.130

+0.480+8.50%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ardelyx Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ardelyx Inc's Score

Industry at a Glance

Industry Ranking

23 / 407

Overall Ranking

82 / 4608

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

11.818

Target Price

+109.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Ardelyx Inc Highlights

StrengthsRisks

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 539.62% year-on-year.

Undervalued

The company’s latest PE is -26.14, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 167.29M shares, decreasing 13.39% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 104.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 110.33M, representing a year-over-year increase of 12.30%, while its net profit experienced a year-over-year increase of 19.78%.

Score

Industry at a Glance

Previous score

8.50

Change



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Ardelyx Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.93, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -26.14, which is -75.80% below the recent high of -6.33 and -273.22% above the recent low of -97.58.

Score

Industry at a Glance

Previous score

7.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 23/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Ardelyx Inc is 11.00, with a high of 16.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

11.818

Target Price

+109.17%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Ardelyx Inc

ARDX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 8.95, which is higher than the Biotechnology & Medical Research industry's average of 6.78. Sideways: Currently, the stock price is trading between the resistance level at 6.94 and the support level at 5.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.24

Change

1.71

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.192

Buy

RSI(14)

62.404

Neutral

STOCH(KDJ)(9,3,3)

53.965

Buy

ATR(14)

0.394

High Vlolatility

CCI(14)

77.056

Neutral

Williams %R

32.967

Buy

TRIX(12,20)

0.262

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

5.794

Buy

MA10

5.652

Buy

MA20

5.379

Buy

MA50

5.690

Buy

MA100

5.288

Buy

MA200

5.000

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 68.85%, representing a quarter-over-quarter decrease of 7.94%. The largest institutional shareholder is The Vanguard, holding a total of 18.31M shares, representing 7.54% of shares outstanding, with 24.78% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

15.98M

+6.92%

BlackRock Institutional Trust Company, N.A.

16.39M

+3.23%

Janus Henderson Investors

15.06M

-39.71%

Macquarie Investment Management

11.46M

+2.68%

Marshall Wace LLP

11.25M

+34.19%

State Street Investment Management (US)

9.84M

-3.29%

Millennium Management LLC

11.66M

+80.40%

Geode Capital Management, L.L.C.

5.67M

-0.11%

BofA Global Research (US)

4.36M

+161.92%

Nuveen LLC

3.47M

+2.36%

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 6.35, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.56. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.